See What HealthDay Can Do For You
Contact Us

Infection Risk Lower for Etanercept Vs Monoclonal Ab Rx

Findings from meta-analysis of patients with rheumatoid arthritis

syringe

THURSDAY, Feb. 9, 2017 (HealthDay News) -- For patients with rheumatoid arthritis, etanercept is associated with lower risk for general infections and tuberculosis compared with monoclonal antibody treatment, according to a meta-analysis published online Feb. 3 in the International Journal of Rheumatic Diseases.

Hongxing Liao, from the Meizhou People's Hospital in China, and colleagues conducted a systematic literature review to examine the differences between monoclonal antibodies and the soluble receptor for infections in patients with RA. Twelve studies were included that reported infections in patients with RA treated with the soluble receptor etanercept or at least one monoclonal antibody (infliximab or adalimumab).

The researchers found that the soluble receptor was associated with a lower incidence rate of serious infection compared with monoclonal antibodies (relative risk, 0.63), although there was high heterogeneity (I² = 85 percent) and the possibility of publication bias. The pooled analysis showed that the soluble receptor was associated with lower risk of tuberculosis (relative risk, 0.19), with low heterogeneity (I² = 0 percent) and no publication bias. Etanercept was associated with lower risk than mono-antibodies for general infections (relative risk, 0.66) with high heterogeneity (I² = 79 percent).

"More well-designed long-term prospective studies would be important to strengthen these findings," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.